Cwm Has Trimmed By $3.86 Million Its Ball (BLL) Position; Biohaven Pharmaceutical Holding Company LTD. Commo (BHVN) Shorts Increased By 97.31%

May 18, 2018 - By Louis Casey

Ball Corporation (NYSE:BLL) Logo

Biohaven Pharmaceutical Holding Company LTD. Commo (NYSE:BHVN) had an increase of 97.31% in short interest. BHVN’s SI was 3.04M shares in May as released by FINRA. Its up 97.31% from 1.54 million shares previously. With 2.38M avg volume, 1 days are for Biohaven Pharmaceutical Holding Company LTD. Commo (NYSE:BHVN)’s short sellers to cover BHVN’s short positions. The SI to Biohaven Pharmaceutical Holding Company LTD. Commo’s float is 18.44%. The stock increased 1.14% or $0.34 during the last trading session, reaching $30.29. About 312,372 shares traded. Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) has 0.00% since May 18, 2017 and is . It has underperformed by 11.55% the S&P500.

Cwm Llc decreased Ball Corp (BLL) stake by 95.52% reported in 2017Q4 SEC filing. Cwm Llc sold 104,358 shares as Ball Corp (BLL)’s stock rose 3.21%. The Cwm Llc holds 4,893 shares with $185,000 value, down from 109,251 last quarter. Ball Corp now has $13.27B valuation. The stock decreased 0.42% or $0.16 during the last trading session, reaching $37.99. About 1.68 million shares traded. Ball Corporation (NYSE:BLL) has risen 6.31% since May 18, 2017 and is uptrending. It has underperformed by 5.24% the S&P500.

Since January 5, 2018, it had 1 buy, and 10 insider sales for $1.64 million activity. Shares for $360,900 were bought by Fisher Daniel William. Shares for $98,900 were sold by STRAIN ROBERT D on Friday, February 23. $86,202 worth of stock was sold by MORRISON SCOTT C on Wednesday, February 21. HAYES JOHN A also sold $261,823 worth of Ball Corporation (NYSE:BLL) shares. Another trade for 2,200 shares valued at $89,562 was made by HOOVER R DAVID on Wednesday, March 7. Peterson James N also sold $170,532 worth of Ball Corporation (NYSE:BLL) shares. $735,919 worth of stock was sold by Pauley Lisa Ann on Thursday, February 22.

Among 14 analysts covering Ball Corporation (NYSE:BLL), 10 have Buy rating, 0 Sell and 4 Hold. Therefore 71% are positive. Ball Corporation had 38 analyst reports since October 15, 2015 according to SRatingsIntel. The stock of Ball Corporation (NYSE:BLL) earned “Buy” rating by Jefferies on Friday, June 23. On Thursday, July 14 the stock rating was initiated by Barclays Capital with “Equal-Weight”. The firm earned “Buy” rating on Tuesday, July 18 by Deutsche Bank. The stock of Ball Corporation (NYSE:BLL) has “Outperform” rating given on Thursday, December 3 by Wells Fargo. The rating was downgraded by Vertical Research on Friday, August 5 to “Hold”. The rating was maintained by BMO Capital Markets with “Hold” on Thursday, April 13. The firm earned “Hold” rating on Wednesday, July 19 by BMO Capital Markets. The firm earned “Neutral” rating on Friday, August 5 by Citigroup. Jefferies maintained the stock with “Buy” rating in Thursday, August 3 report. UBS initiated the stock with “Buy” rating in Monday, October 23 report.

Another recent and important Ball Corporation (NYSE:BLL) news was published by Seekingalpha.com which published an article titled: “Ball Corporation Not Quite On The Ball Yet” on April 23, 2018.

Cwm Llc increased Merck & Co Inc (NYSE:MRK) stake by 7,717 shares to 97,003 valued at $5.46 million in 2017Q4. It also upped Powershares Etf Tr Ii (PCY) stake by 89,144 shares and now owns 89,797 shares. Spdr Index Shs Fds (GMM) was raised too.

Analysts await Ball Corporation (NYSE:BLL) to report earnings on August, 2. They expect $0.60 earnings per share, up 13.21% or $0.07 from last year’s $0.53 per share. BLL’s profit will be $209.55M for 15.83 P/E if the $0.60 EPS becomes a reality. After $0.50 actual earnings per share reported by Ball Corporation for the previous quarter, Wall Street now forecasts 20.00% EPS growth.

Investors sentiment decreased to 1.31 in Q4 2017. Its down 0.03, from 1.34 in 2017Q3. It is negative, as 33 investors sold BLL shares while 129 reduced holdings. 75 funds opened positions while 138 raised stakes. 292.68 million shares or 3.20% less from 302.34 million shares in 2017Q3 were reported. Retirement Of Alabama has 0.03% invested in Ball Corporation (NYSE:BLL). First Quadrant Limited Partnership Ca has 220,204 shares for 0.16% of their portfolio. Palisade Asset Mgmt invested in 1.38% or 230,449 shares. Profund Advsrs Ltd Liability Com stated it has 11,445 shares. Blair William & Company Il reported 38,218 shares stake. Howe Rusling owns 4,406 shares. Great West Life Assurance Can holds 241,060 shares. Zurcher Kantonalbank (Zurich Cantonalbank) has 59,628 shares for 0.02% of their portfolio. New York-based Metropolitan Life Insurance Com has invested 0.03% in Ball Corporation (NYSE:BLL). Franklin Res Incorporated has invested 0.01% of its portfolio in Ball Corporation (NYSE:BLL). 36,046 are held by Fragasso Grp. Dnb Asset Mgmt As has invested 0.02% in Ball Corporation (NYSE:BLL). Thomas White Ltd has invested 0.17% in Ball Corporation (NYSE:BLL). Shelton Cap stated it has 22,168 shares or 0.05% of all its holdings. Ascend Capital Ltd Limited Liability Company reported 574,235 shares stake.

Among 2 analysts covering Biohaven Pharmaceutical (NYSE:BHVN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Biohaven Pharmaceutical had 2 analyst reports since May 31, 2017 according to SRatingsIntel. The stock of Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) earned “Overweight” rating by Morgan Stanley on Wednesday, May 31. Canaccord Genuity initiated the stock with “Buy” rating in Friday, December 15 report.

More notable recent Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) news were published by: Seekingalpha.com which released: “Your Daily Pharma Scoop: Biohaven Updates, MEIP Offering, Kite European Expansions” on May 17, 2018, also Prnewswire.com with their article: “Biohaven Pharmaceuticals Reports First Quarter 2018 Financial and Recent Business Results” published on May 15, 2018, Streetinsider.com published: “Biohaven (BHVN) to Present Additional Phase 3 Rimegepant Data at AAN 2018 on April 22nd” on April 19, 2018. More interesting news about Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) were released by: Globenewswire.com and their article: “Factors of Influence in 2018, Key Indicators and Opportunity within BIOHAVEN PHARM, WEC Energy Group, Axon …” published on April 19, 2018 as well as Seekingalpha.com‘s news article titled: “Biohaven announces secondary endpoint results from Phase 3 clinical trials BHV3000-301 and 302 of Rimegepant” with publication date: April 23, 2018.

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. The company has market cap of $1.17 billion. The Company’s advanced product candidate includes rimegepant, which is intended to initiate two Phase III clinical trials for the acute treatment of migraine; and trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia. It currently has negative earnings. The firm also develops BHV-3500 for the prevention of chronic and episodic migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities.

Ball Corporation (NYSE:BLL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: